Skip to content

BCG vaccine use to prevent COVID-19 in health care workers

BCG vaccine as preventive measure against COVID-19 in health care workers

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
REBEC
Registry ID
RBR-5ysj54
Enrollment
Unknown
Registered
2020-07-27
Start date
2020-07-15
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus infection unespecific localization

Interventions

Experimental group: 500 heathcare workers will be vaccinated with BCG vaccine and will have a follow-up for the next 6 months in 2 moments or when necessary Control group:500 heathcare workers will be
Biological/vaccine

Sponsors

Universidade Federal do Rio de Janeiro
Lead Sponsor
Universidade do Estado do Rio de Janeiro
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Individuals aged above 18 years old, male or female, not infected with SARS-CoV-2 who exercise professional activities in the Health Units of the study; Agreement to participate in the study by signing the informed consent form

Exclusion criteria

Exclusion criteria: Professionals with a history of infection confirmed by SARS-CoV-2 or who have already been diagnosed with COVID-19 prior to the study; Individuals who have not performed confirmatory tests for COVID-19; Pregnancy or breast-feeding; Non-permanence in activities in the Health Units after 6 months of enrollment in the study; Individuals with primary or acquired immunodeficiency; Individuals with malignant neoplasms; Patients on high-dose corticosteroids (equivalent to a prednisone dose of 20 mg / day or more) for more than two weeks; Patients using other immunosuppressive therapies (antineoplastic chemotherapy, radiation therapy, among others); Individuals with autoimmune diseases; Dermatological disorders at the vaccine site or generalized; Individuals under treatment for active tuberculosis; Individuals with report of fever (axillary temperature> 38 ° C in the last 48h)

Design outcomes

Primary

MeasureTime frame
It is expected to find a smaller number of coronavirus infections in the BCG vaccinated group when compared to those vaccinated with placebo;It is expected to find a smaller number of severe coronavirus infections in the BCG vaccinated group when compared to those vaccinated with placebo

Secondary

MeasureTime frame
Assess the immune response mediated by the BCG vaccine in healthcare professionals

Countries

Brazil

Contacts

Public ContactFernanda;Fernanda Mello;Mello

UNiversidade Federal do Rio de Janeiro;Universidade Federal do Rio de Janeiro

fcqmello@gmail.com;fcqmello@gmail.com5502139382887;2139382887

Outcome results

None listed

Source: REBEC (via WHO ICTRP)